Researchers at the Max Delbrück Center have reported promising progress in a therapy aimed at reversing heart stiffness in the most prevalent form of cardiac failure, heart failure with preserved ejection fraction.
The investigational drug, known as RBM20-ASO, works at a genetic level to restore the heart’s ability to relax and refill between beats.
This finding could change how cardiologists approach diastolic dysfunction, a condition that has resisted effective pharmacological treatments for decades.
Unlike conventional heart drugs focused on pumping strength, this therapy targets the molecular flexibility of cardiac muscle tissue, potentially tackling the root cause of stiffness.
What makes HFpEF so difficult to treat
Heart failure with preserved ejection fraction, or HFpEF, primarily affects older adults whose hearts remain able to pump blood normally but fail to relax adequately after each contraction.
This restricted relaxation leads to breathlessness, fatigue, and reduced exercise tolerance. Current medications relieve symptoms but have a limited effect on outcomes.
HFpEF is often associated with other chronic conditions such as obesity, hypertension, and diabetes. These comorbidities accelerate changes in the cardiac extracellular matrix, making the heart muscle stiffer over time.
Researchers have struggled to design drugs that target the molecular mechanics behind this stiffness.
Did you know?
The human titin protein is the largest known protein, spanning half the length of a cardiac sarcomere and containing more than 38,000 amino acids.
How RBM20 affects heart muscle stiffness
The RBM20 gene regulates splicing of titin, a giant protein that functions like a spring inside each cardiac muscle cell. In its stiff variant, titin limits the heart’s ability to stretch and refill with blood.
When RBM20 activity is reduced, the heart produces a more elastic version of the protein, improving compliance without weakening contraction.
In antisense therapy, scientists use single-stranded molecules to suppress RBM20 messenger RNA specifically.
By moderating its expression, the heart’s natural elasticity can be restored, allowing diastolic filling to recover while maintaining systolic performance.
Why titin elasticity matters in cardiac function
Titin’s mechanical properties determine how the heart muscle behaves under strain. In healthy young hearts, the protein’s elastic form ensures the ventricle expands easily during relaxation.
As people age, changes in RBM20 control lead to an accumulation of rigid titin isoforms, reducing diastolic flexibility.
Boosting the expression of elastic titin helps the heart behave more youthfully, enhancing its ability to handle blood volume changes during normal circulation.
Importantly, this adjustment does not rely on hemodynamic manipulation but directly treats the molecular flexibility deficit.
ALSO READ | Study reveals pain relief with single low-dose radiation for knees
What the animal studies reveal about RBM20-ASO
The research team conducted extensive testing in mouse models that replicate both genetic and metabolic forms of HFpEF. Treatment with RBM20-ASO significantly increased titin elasticity, allowing the ventricles to expand more effectively between contractions.
The mice exhibited improved diastolic performance even while maintaining normal systolic function.
Moreover, moderate dosing achieved this benefit without strong immune activation. The drug reduced left ventricular stiffness and counteracted abnormal myocardial thickening.
Importantly, even animals with persistent comorbidities, such as high blood pressure and obesity, responded positively.
Where the research could go next
Scientists plan to advance these results toward large-animal studies before initiating human trials. The following experimental stage will evaluate safety and dose intervals in a porcine model that more closely mirrors human heart physiology.
If validated, this could represent the first disease-modifying therapy for HFpEF that operates through precision molecular repair.
Researchers also foresee broader use of antisense oligonucleotide strategies to fine-tune other heart proteins related to elasticity and signal coordination.
Such therapies could offer new hope to millions of aging adults suffering from diastolic heart failure worldwide.
If successful, RBM20-ASO may pioneer a class of cardiac gene medicines focused not on forcing performance but on restoring balance and natural motion, marking a fresh era in cardiovascular therapeutics.
Comments (0)
Please sign in to leave a comment